Pfizer Ends Weight Loss Trial

This is a news story, published by CNBC, that relates primarily to Pfizer news.

Pfizer news

For more Pfizer news, you can click here:

more Pfizer news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

elevated liver enzymes

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest liver enzymes news, other obesity drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

other weight loss drugs

CNBC

•

Health

Pfizer scraps daily weight loss pill after liver injury in one patient

Summary

Nutrition label

87% Informative

Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial.

The patient's liver enzymes "recovered rapidly" after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron .

Pfizer is among several drugmakers racing to bring a more convenient weight loss medicine to a space dominated by weekly injections.

Pfizer 's announcement Monday comes as the company regains its footing and recovers its share price after the rapid decline of its Covid business. Pfizer is betting on its pipeline of cancer drugs to deliver long-term growth, but has emphasized that obesity is a key focus..

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful